title: [Differences in the prognosis according to the periods of diagnosis in ulcerative colitis].
abstract: OBJECTIVE
  Infliximab was approved for the treatment of ulcerative colitis (UC) in 2006 and has recently been used as rescue therapy in steroid-refractory UC. The aim of this study was to investigate the differences of medication use and prognosis in UC patients according to the periods of diagnosis.
  
  
  METHODS
  From 1987 to 2012, a total of 1,422 patients with UC were retrospectively reviewed in 12 hospitals. The study population was divided into two groups according to the periods of diagnosis as follows; group A: 1987-2005, group B: 2006-2012. Analyzed variables were compared by using chi-square test and logistic regression analysis.
  
  
  RESULTS
  Mean age of the subjects was 42.2 years, and the mean follow-up period was 4.7 years. In univariate analysis, the use of infliximab in group B was significantly higher than group A (4.5% vs. 7.6%, p=0.016), and UC-related hospitalization (45.8% vs. 40.1%, p=0.031) and UC-related surgery (6.4% vs. 3.5%, p=0.010) in group B was significantly lower than that of group A. The use of oral steroid in surgery group was significantly higher than non-surgery group in multivariate analysis (OR 1.85, 95% CI 1.03-3.30, p=0.039).
  
  
  CONCLUSIONS
  Infliximab might play an important role for the treatment of steroid-refractory UC. Well-designed prospective trials based on the efficacy and safety of infliximab are required in the future.
authors.affiliation: Department of Medicine, Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 110-746, Korea.
authors.forename: Hyun Beom
authors.initials: HB
authors.lastname: Chae
authors.forename: Yoon Suk
authors.initials: YS
authors.lastname: Jung
authors.forename: Dong Il
authors.initials: DI
authors.lastname: Park
authors.forename: Chang Kyun
authors.initials: CK
authors.lastname: Lee
authors.forename: Kyu Chan
authors.initials: KC
authors.lastname: Huh
authors.forename: Jeong Eun
authors.initials: JE
authors.lastname: Shin
authors.forename: Jae Hak
authors.initials: JH
authors.lastname: Kim
authors.forename: You Sun
authors.initials: YS
authors.lastname: Kim
authors.forename: Yunho
authors.initials: Y
authors.lastname: Jung
authors.forename: Sung Ae
authors.initials: SA
authors.lastname: Jung
authors.forename: Hyun Ju
authors.initials: HJ
authors.lastname: Song
authors.forename: Hyun Joo
authors.initials: HJ
authors.lastname: Jang
authors.forename: Sung Noh
authors.initials: SN
authors.lastname: Hong
authors.forename: Young Ho
authors.initials: YH
authors.lastname: Kim
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006760:Hospitalization; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use; D016015:Logistic Models; D008297:Male; D019804:Mesalamine / Q000627:therapeutic use; D008875:Middle Aged; D016017:Odds Ratio; D011379:Prognosis; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine; D000069285:Infliximab